Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese childhood AML cooperative study group

Kazuko Kudo, Seiji Kojima, Ken Tabuchi, Hiromasa Yabe, Akio Tawa, Masue Imaizumi, Ryoji Hanada, Kazuko Hamamoto, Ryoji Kobayashi, Akira Morimoto, Hideki Nakayama, Masahiro Tsuchida, Keizo Horibe, Hisato Kigasawa, Ichiro Tsukimoto

Research output: Contribution to journalArticlepeer-review

71 Citations (Scopus)

Abstract

Purpose: To evaluate a less intensive chemotherapeutic regimen specifically designed for patients with Down syndrome (DS) and acute myeloid leukemia (AML), and to determine the prognostic factors for event-free survival. Patients and Methods: Seventy-two patients with AML-DS were treated with remission induction chemotherapy consisting of pirarubicin (25 mg/m2/d for 2 days), cytarabine (100 mg/m2/d for 7 days), and etoposide (150 mg/m 2/d for 3 days). Patients received four courses of intensification therapy of the same regimen. Prophylaxis for CNS leukemia was not included. Results: All but two patients were younger than 4 years, and 67 of the 72 patients (93%) were diagnosed as acute megakaryoblastic leukemia (AMKL). Seventy of the 72 patients (97.2%) achieved a complete remission (CR), and the estimated 4-year event-free survival (EFS) rate was 83% ± 9%. Nine patients relapsed, and one died as a result of pneumonia during CR. Multivariate analysis revealed that the presence of monosomy 7 was a greater risk factor of adverse outcome (odds ratio = 5.67; P = .027). Conclusion: A less intensive chemotherapeutic regimen produces excellent outcomes in standard-risk AML-DS patient. Risk-oriented therapy should be considered for future trials in AML-DS.

Original languageEnglish
Pages (from-to)5442-5447
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number34
DOIs
Publication statusPublished - 01-12-2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese childhood AML cooperative study group'. Together they form a unique fingerprint.

Cite this